REGISTER TOday! - Bentham Science

2012年亚洲生物仿制药会议 

23–26 April 2012, Grand Hyatt Shanghai, China 

2012年4月23-26 日,中国上海金茂君悦大酒店 

Partnership and Commercializing Strategies for Increased Market Uptake 

推进合作与商业化战略,拓展产品市场份额 

Featuring 

Regulatory Keynote 

Suzette Kox, Senior Director Scientific Affairs, 

European Generic Medicines Association 

(EGA), Belgium 

Investor Keynote 

Julie Seawall, Executive Director, 

Business Development, Merck 

BioVentures, USA 

Industry Leaders 

Other Industry Perspectives 

Thomas Moriarty, President, Global Pharma Strategies, 

Medco, USA 

Alan Sheppard, Principal, Global Generics, Thought 

Leadership, IMS Health, UK 

Co-Located with: 

第四届2012中国疫苗会议 china 2012 

Produced by 

dr Arthur Alston, Regulatory Affairs, 

Special Projects, Roche, Switzerland 

dr Subir Basak, Chief Executive Officer, 

Celestial Biologicals Limited, Chief Commercial 

Officer, Intas Biopharmaceuticals Ltd, India 

dr Stanley Hong, Senior Vice President, Research 

& Development, Celltrion, South Korea 

Michael Corbo, Vice President & Chief 

Development Officer, Bio-enhancement 

Development Unit, pfizer, USA 

an informa business 

Knowledge Partner 

Why bioSimiLarS aSia iS 

bio-better in 2012! 

Asia’s LARGEST meeting on Biosimilars: Over 30 speakers in 24 powerpacked 

sessions; over 150 attendees in 2011 

ONLY conference in Asia with multiple-player perspectives: Innovators + 

Biopharmas + Biosimilar players + Investor + Pharmacy Benefit 

Management + Regulatory 

2012 fOCuS is on: commercial viability, investment evaluations, strategic 

collaborations, prescribers’ acceptance 

uNIquE IN-dEpTH case studies by Industry leaders: Celltrion, Merck 

Bioventures and more in their quest for global biosimilars 

MORE pHARMERGING MARKET perspectives alongside GLOBAL 

speakers from US, Europe, Japan, Syria, Pakistan, China, India 

EXCLuSIVE IMS intelligence presented and explored during the 

conference and Post Conference Briefing 

Maximized networking and collaboration opportunities from 

3 CO-LOCATEd CONfERENCES under the same roof! 

pre-Conference 

full day Workshop 

23 April 2012 

post-Conference 

full day Strategy 

Briefing 

26 April 2012 

www.biosimilarsasia.com 

Literature Insertion Sponsor 

Media Partners 

PLuS! not to be miSSed! 

RegistRation hotline +65 6508 2401 / +86 21 2326 3680 

This conference will be simultaneously translated 此会议将会有中英同声翻译 

US Market Entry: A Regulatory, Legal, and Medical 

Communication Perspective 

Led By: 

Seth J Goldenberg, President, Asia pacific Bio Intelligence,& former uS fdA, pharmacology 

Michael platt, President, MedVal Communications 

Gary Smith, Founder, Enterprise Law 

Turning Strategies into Tactical Plans 

to Optimize Market Entry – Balancing 

Commercial, Regulatory and Investments to 

Deliver Successful Business Models 

Led By: 

Alan Sheppard, Global Head of Generics, Thought Leadership, IMS Health 

Richard diCicco, Chairman, Harvest Moon pharmaceuticals uSA, Inc 

dr Janet M McNicholas, Partner, K&L Gates LLp 

Official Associations 

Part of 

International Marketing Partner 

www.ibc-asia.com

The estimated US$80bn of biologics coming off patent by 2020 is not a sum the 

pharmaceutical industry can risk ignoring. In addition, the extended global financial crisis has 

increased pressure on healthcare regimes, regulators and pharma to bring more affordable 

and accessible drugs to market. 

Innovators are fighting to stave off losses and protect their market share against intensifying 

competition. Meanwhile, regulators and prescribers are forced to evaluate interchangeability, 

bioequivalence and quality compared to premium priced originator drugs. In these 

unprecedented times, the commercial viability, sustainability and market potential of 

biosimilars have become a point of contention. 

IBC’s 3rd Annual biosimilars asia 2012 is the largest and most anticipated meeting of its 

kind in Asia. Attended by biosimilars, innovators, generics and biopharma alike, the unique 

mix of attendees from all over the world will share their experiences and opinions about the 

future of biosimilars. Tough questions will be answered and positions will be challenged but 

all will walk away bristling with ideas, opportunities and be more informed. biosimilars 

asia 2012 continues to deliver a quality of speakers and discussions unmatched in Asia. 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 




Partnership and Commercializing Strategies for Increased Market Uptake 推进合作与商业化战略,拓展产品市场份额 

10 Reasons 

why Biosimilars asia is a 

‘mUsT aTTEND’ 

Biosimilars Asia 2012 is Asia’s LARGEST CONfERENCE 

addressing complex strategy questions, attended by regional 

and global innovators, generics, biopharma and biosimilars 

companies 

STRATEGIC pLENARY KEYNOTE SESSIONS with delegates 

from Biosimilars Asia 2012, China Pharmaceutical R&D 

Summit & Vaccines China 2012 

dON’T MISS OuT on ‘no-holds-barred’ discussions featuring 

innovators, generics, biosimilars and industry thoughtleaders! 

Get a global point of view of the fuTuRE Of BIOSIMILARS 

with speakers from the USA, EU, Asia, MENA 

Meet the GREATEST NuMBER of Asian and pharmerging 

markets’ biosimilar companies under one roof 

With imminent global regulatory changes, find out the 

LATEST in the US, Europe and China 

Be privy to STRATEGIES in collaborations, countering 

aggressive price cuts and increasing market acceptance of 

biosimilars 

Determine the COMMERCIAL VIABILITY of biosimilars 

REVIEW the challenges, opportunities and success factors in 

launching biosimilars 

The ONLY EVENT featuring frank and honest debates, 

invaluable insights and unmatched collaboration 

opportunities 

2012 年亚洲生物仿制药会议 

“不容错过”的十大理由 

2012年亚洲生物仿制药会议是亚洲地区致力于解决生物仿制药产 

业复杂战略问题的最大规模会议,本地区乃至全球的创新机构、 

仿制药企业、生物创新药和生物仿制药公司均会出席 

出席2012年亚洲生物仿制药会议、中国药物研发峰会和 

2012年中国疫苗会议的代表将共同出席战略性主题演讲 

千万不要错过与创新机构、仿制药企业、生物仿制药公司和业 

界思想领袖“无拘无束”探讨问题的机会! 

聆听美国、欧盟、亚洲、和中东地区演讲者的精彩发言,了解关 

于生物仿制药未来发展的全球观点 

在同一地点结识众多亚洲和新兴医药市场生物仿制药公司代表 

了解即将出现的全球监管变革,探索美国、欧洲和中国的最新 

监管趋势 

洞察业界合作、反击大幅度降价行为以及提高生物仿制药市场 

认同度的各项策略 

确定生物仿制药的商业可行性 

审视生物仿制药上市过程中所面临的挑战、机遇和成功因素 

这是唯一一个能够让彼此坦诚交流的会议,您可以在此聆听真 

知灼见,寻求无比宝贵的合作机会 

2012 gLOBAL SPEAkERS InCLUDE: 

Yariv Hefez 

Director, Global Business Development 

and Alliance Management, Merck 

Serono, Switzerland 

dr Yang Xu 

Chief Patent Counsel, Simcere 

Pharmaceutical Group, China 

dr Sunit Maity 

Associate Divisional Head, 

biopharmaceuticals, Avesthagen, 

India 

Youling Wu 

CEO, ZheJiang Teruisi, 

China 

PhARMERgIng REgIOnAL FORECAST 

Source: IMS Health, Nov 2011 

WhO ShOULD ATTEnD: 

By JoB TiTle 

CEO, CSO, VPs, Directors & Heads of 

• Research & Development 

• Business Development & Strategy 

• Follow-on Biologics/Follow on Proteins/ 

Biosimilars 

• Biologics/Biotechnology/Biogenerics 

• IP Director/Counsel Lawyer & Patent 

• Sales & Marketing 

• Product Development 

• Strategy Planning & Development 

• Licensing 

• Procurement / Sourcing 

• External Manufacturing 

• Clinical Trials 

• Collaborative Research 

• CMO Account Management 

• External Resourcing 

• Quality Assurance 

• Technology Transfer Lead 

• Pharmacovigilance 

价值 800 亿美元的生物制剂产品专利将陆续在2020年之际到期。这一改变牵涉数额如此巨 

大,将对制药行业产生深远影响。与此同时,伴随全球金融危机影响范围持续扩大,医疗 

保健行业、监管机构和制药企业所面临的压力不断增加,促使其在市场上推出价格更便 

宜、更容易买到的药品。 

创新机构努力在日趋激烈的竞争中避免损失,并尽力维护其占有的市场份额。同时,监管 

机构和处方医师不得不以价格高昂的原研药作为参照,对药物的可替代性、生物等效性和 

质量进行评估。在这一前所未有的特殊时期,生物仿制药的商业可行性、可持续性和市场 

潜力成为了争论的焦点。 

由 IBC 主办的 2012年亚洲生物仿制药会议是亚洲地区同类会议中规模最大、参与程度最 

高的一次盛会。来自世界各地的生物仿制药企业、创新机构、仿制药公司和生物制药企业 

代表齐聚一堂,积极分享彼此的经验和对生物仿制药未来发展的看法。此次会议将深入探 

讨众多棘手的问题,积极汇聚业界各方的观点,所有与会者必能带着更多资讯、见解和机 

遇满载而归。2012年亚洲生物仿制药会议将沿袭以往的出色水准,汇聚亚洲地区最高级别 

的与会者与畅所欲言的热烈讨论。 

PhArMergIng cOuntry grOwth dynAMIcS 

Carl firth 

CEO, Aslan Pharmaceuticals, 

Singapore 

dr Mary Haak-frendscho 

President and Chief Scientific 

Officer, Takeda San Francisco, 

USA 

dr Shahzad Khan 

Director, Marketing & Sales, 

Getz Pharma, Pakistan 

Abdullah Baaj 

CEO, Boston Oncology, 

Syria 

Shirley Zhao 

General Manager, 

Genzyme, China 

dr Ming Wang 

Executive Director and Head of 

Diabetes Research, Amgen, USA 

dr Kyu don Kim 

Vice President, Strategic 

Business Development, 

Samsung, South Korea 

dr Junichi Koga 

Vice President 

Biopharmaceuticals, 

Daiichi-Sankyo, Japan 

REGISTER NOW! Online www.biosimilarsasia.com or call our Customer Service Hotline: +65 6508 2401 / +86 21 2326 3680 

Others 12% 

Part of 

By indusTry By counTry 

Regulatory 

authorities & 

Ministry of Health 

2% 

Contract 

Manufacturing 

Organizations 

4% 

Contract Research 

Organizations 4% 

Generics & Biosimilar 

Companies 30% 

Pharmaceuticals 25% 

Biotechnology & 

BioPharmaceuticals 

23% 

“In 2009, the combined biosimilars market 

size for the US and five major European 

markets was US$150m. With more than 30 

branded biologics with sales of US$51bn set 

to lose patent exclusivity between 2011 and 

2015, the global biosimilar market will grow 

from US$243m in 2010 to US$3.7bn in 2015.” 

Datamonitor, April 2011 

“2009 年,美国和欧洲五个主要市场的生物仿 

制药整体市场规模为 1.5 亿美元。在 2011 年至 

2015 年期间,销售额高达 510 亿美元的 30 多 

种品牌生物制剂将失去独家专利权,而全球生 

物仿制药市场规模将从 2010 年的 2.43 亿美元 

飙升至 2015 年的 37 亿美元。” 

Thailand 1% 

Syrian 2% 

Singapore 

9% 

Pakistan 

3% 

Malaysia 

1% 

USA 4% 

Taiwan 9% 

Korea 10% 

Japan 7% 

Iran 5% 

Datamonitor,2011 年 4 月 

Australia 2% 

Switzerland 4% 

China 30% 

India 9% 

Germany 1% 

United Kingdom 1% 

Hong Kong 1% 

Ireland 1%


ExhIBITIOn FLOORPLAn 

Reserve 

your booths 

today! 

AM 

PM 

MON 23 APRIL TUE 24 APRIL WED 25 APRIL THU 26 APRIL 

Pre-Conference Workshops: 

US Market Entry: A Regulatory, 

Legal, and Medical Communication 

Perspective (Full Day) 

Expression Systems for Antibody and 

Vaccine Biomanufacturing (Full Day) 

LUNCH, 

AM & PM BREAKS 

US Market Entry: A Regulatory, 

Legal, and Medical Communication 

Perspective 

Expression Systems for Antibody and 

Vaccine Biomanufacturing 

Meet the Speakers Reception 

(by Invitation only) 

16 

Onsite 

Lab 

China Pharmaceutical R&D 

Summit 

• Regulatory Snapshots 

• R&D Leaders Panel 

• Investment & Funding 

• ‘Pharma Idol’: Innovation 

Showcase 

• CXO Panel Discussion 

• Funding for Innovation 

REGISTER TOday! 

1 2 3 

Biosimilars 

15 

Tea/ Coffee 

Station 

14 

PAST ATTEnDIng COMPAnIES InCLUDE: 

drug diScovery & deveLoPment Week event at a gLance 

China Pharma R&D, Vaccines & Biosimilars 

JOINT PLENARY SESSION 

Global and Regional Keynote Presentations 

On Pharma R&D 

Vaccines China 

• Market Trends & Outlook 

• Vaccines Quality Control & 

Compliance 

• Novel Development of Vaccines 


• Visionary Panel Discussion 

Discussion Den: 

In depth roundtable discussions on Regulatory and 

Collaborations in Key Asian Countries 

4 

China 

Pavilion 

13 

NETWORKING RECEPTION 

EVENING DINNER (Optional) 

+65 6508 2401 

+86 21 2326 3680 

Tea/ Coffee 

Station 

12 

5 6 7 

Vaccines 

CRO 

Clinic 


Summit 

• Drug Development & 

Partnering Strategies 

• Emerging Business Models 

in R&D 

• Discovery & Early Stage Devt 

• Role of Academia in Drug 

Discovery & Development 

EXHIBITION & POSTER SESSION 

DISCUSSION DEN 

CRO Clinic / Onsite “Lab’ & Demonstrations 

China Technology & Services Pavilion 

Biosimilars Asia 

• Market Entry & Opportunities 

• Commercial Viability 


• Visionary Panel Discussion 

Tea/ Coffee 

Station 

Networking 

Lounge 

GENENTECH • ASAHI GLASS • SINOPHARM • USV • JCR PHARMACEUTICALS • MAIN LUCK PHARMACEUTICALS • 

HANWHA CHEMICAL • SANDOZ • BOEHRINGER INGELHEIM • GLAXOSMITHKLINE • LUPIN • HOSPIRA • MYCENAX 

BIOTECH • MERCK & CO • DR REDDY’S LABORATORIES • SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL • 

SHANGHAI CELGEN BIOPHARMACEUTICALS • ELI LILLY • TTY BIOPHARM • 3SBIO • JIANGSU CHIA TAI TIANQING 

PHARMACEUTICAL • PFIZER INVESTMENT • NIPPON KAYAKU • HENLIUS BIOPHARMACEUTICALS • SHANGHAI 

HENLIUS BIOTECH • RANBAXY • ASTRAZENECA • BECTON DICKINSON (BD BIOSCIENCES) • F HOFFMANN-LA 

ROCHE • CIPLA • GETZ PHARMA • MATRIX (MYLAN) • HISUN PHARMACEUTICAL • COBEL DAROU • SAMSUNG • 

SANOFI-AVENTIS • STADA • GENZYME • ADV BIOSCIENCE • BIOGEN IDEC • FOSUN PHARMA • DAIICHI-SANKYO 

SPOnSORShIP OPPORTUnITIES 

Raise awareness for your services available to 

Asian pharmaceuticals! 

• Do you find difficulty in reaching senior decision makers and 

successfully stimulating interest for your services? 

• Are you trying to raise awareness of the value of your company’s 

expertise and services? 

• Or are you finding it difficult to differentiate your company from 

your competition? 

Perhaps what you need is a branding opportunity at this event! 

Increase your reach through our extensive marketing campaign, 

targeted at your qualified business audience. For information about 

placing your brand & profile top-of-mind to key buyers, contact Yvonne 

Leong, Business development Manager on Tel: + 65 6508 2489 / 

yvonne.leong@ibcasia.com.sg 

11 

10 

“Great interaction between biosimilar 

companies, innovator, market 

consultants, regulations, patent 

attorneys etc” 

Rustom, R&D, Intas Pharmaceutical 

“This conference gave us many 

opportunities for networking” 

Jade, Business Development, Hanwha Chemical Corp 

“I enjoyed the knowledge & content from 

the presenters” 

Andrew, Director, Biosimilars Advisory Service & 

Oncology, BioTrends Research Group 

8 

9 


Summit 

• ‘Pharma Idol’: Innovation 

Showcase and Awarding 

• Clinical Development & 

Partnerships in Asia 

• Future Opportunities in 

Biosimilars & Biobetters 

• Closing Visionary Panel 

Discussion 

+65 6508 2407 

+86 21 2326 3699 




Part of: 

Take advantage of the synergy of 3 established events under 

one roof. Develop new contacts in drug development and 

enhance your overall networking experience by showcasing 

your capabilities to get your deals done. Don’t forget your 

business cards! 

Forging successful collaborations & ensuring Quality 

& compliance 

www.vaccineschina.com 

The most comprehensive event focused on vaccines development 

through to manufacturing. Good manufacturing practices and strategies 

will be reviewed, alongside potential block-buster technologies and 

R&D projects. 

Advancing r&d through innovation and collaborations 

www.chinapharmard.com 

China’s first and longest running international conference has brought 

together world-renowned thought-leadership from the West to Asia, 

to expedite and develop collaborations in pharma R&D. While global 

MNCs are firmly established in the region, increasing focus is on 

Asian enterprises, led by overseas returnee-led and China-supported 

companies emerging to research and develop new molecules. As the 

industry globally moves towards biologic medicines and the race to 

deliver affordable post-patent treatments intensifies, this annual 

meeting will highlight the winning pathways to successful Asian R&D 

and commercialization for the region and beyond. 

Combining the best of the West and East, traditional and biopharma, from 

discovery to clinical development and approvals, international, regional 

and Chinese pharma leaders will address the future of innovation and 

map the future growth potential for the industry in Asia as well as Asia’s 

contribution to global R&D. 


• Novel Vaccine Candidates for 

Tropical Diseases 

• Research and Clinical Updates 

for EV71 vaccines 


• Innovations & Technological 

Advancements 

• Future Opportunities 

for Sustainable Return on 

Investment 

Co-located with: 

第四届2012中国疫苗会议 china 2012 

打造成功合作关系,追求卓越质量 Forging successful collaborations and ensuring Quality & compliance 


• External Collaborations & 

Commercial Value 

• Breaking into Protectionist 

Markets 

• Intellectual Property Legal 

Debate 


• Mad about mAbs 

• Developing Biosimilars & 

Biobetters 

• Winning Buy-in 

• Closing Panel Debate 

Part of 

Post-Conference Workshops: 

Next Generation of Vaccine Facilities 

with Focus on Design & Containment 

Turning Strategies into Tactical 

Plans to Optimize Market Entry – 

Balancing Commercial, Regulatory 

and Investments to Deliver Successful 

Business Models 

register@ibcasia.com.sg www.biosimilarsasia.com


0800 Registration & Morning Coffee / Tea 

0830 Chairman’s Opening Remarks 

Li Chen, President & CEO, Hua Medicine, China 

PlenAry KeynoTe sessions: 

GloBAl And reGionAl PHArMA r&d 

0840 Takeda’s R&D Collaboration Model for Targeted Medicine for Unmet needs 

dr Mary Haak-frendscho, President & Chief Scientific Officer, Takeda San francisco, USA 

0910 Extending Innovation network through Partnering 

Joe McCracken, Global Head of Business Development & Licensing, Roche, USA 

gLobaL 

keynote 

addreSS 

0940 Effectively Tackling R&D Productivity Challenge: Integration of External Research 

gLobaL 

keynote 

addreSS 

• Open innovation models 

• Improving innovation for sustainability 

• Innovation in China 

• Industry-Academia and Industry-Biotech partnerships 

• Effectively managing the integration of external research 

• Abandoned R&D assets: value or burden? 

dr Helmut Haning, Senior Vice President & Head Global Innovation Outsourcing, Bayer Healthcare pharmaceuticals, Germany 

1010 Is China Ready to Lead in global Drug Innovation and Development? 

• Is ROCE-led innovation transforming China’s pharma industry onto the world stage? 

• Partnering with China in vaccines research & development 

• Opportunities and challenges from biosimilars and biobetters from/for pharmerging markets 

Moderator: 

Carl firth, CEO, Aslan pharmaceuticals, Singapore 

panelists: 

Ling Chen, Vice President of R&D China Operations, GlaxoSmithKline, China 

frank Shen, Vice President Global Data Management and Statistics, Global Pharmaceutical R&D, Abbott, USA 

Youling Wu, CEO, ZheJiang Teruisi, China 

dr Ming Wang, Executive Director & Head of Diabetes Research, Amgen, USA 

1100 Morning Refreshments 

Exhibition hall & Poster Session Opens 

End of Plenary Session 

1130 Chairperson’s Opening Remarks 

Richard diCicco, Chairman, Harvest Moon pharmaceuticals, USA 

THe FuTure oF BiosiMilArs: MArKeT enTry & oPPorTuniTies 

1140 The Commercial Viability of Biosimilars 

• What are the key considerations before deciding to invest in biosimilars? 

• Determining the commercial value of biosimilars 

• Is it feasible for small to medium sized companies to venture into biosimilars? 

• How has the non-conventional financial backing from the likes of Novartis, Henlius, Samsung Electronics etc changed the 

biosimilars landscape? 


1210 Beyond Borders - Setting Sights unto Semi and Unregulated Pharmerging Markets 

• What are the key considerations to consider before expanding overseas? 

• Is the risk worth it? 

• Best practices to gain the greatest market access such as launch strategies to be first to market 

• Shared value strategies - increasing the odds of reaching more markets 

• What is the affordability of higher-value biosimilars in pharmerging markets with little or no government support and insurance? 

• How to structure an optimal concept development to take into consideration out of pocket investments such as initial licensing fees? 

Moderator: 

dr Tong Zhang, Director, Pan Regional Lead, Emerging Market Business Development, Merck, USA 

panelists: 

Abdullah Baaj, CEO, Boston Oncology, Syria 

Imtiaz Razzaq, Head of Business Development, Getz pharma, Pakistan 

dr peter qian, CEO, Reviva Biopharmaceutics, General Secretary, CBA, USA 

0900 Chairperson’s Opening Remarks 


0910 Is it the Beginning of the End for Biosimilars as We Move Beyond 1st generation Molecules? 

• A review of the ever changing pharmaceutical landscape and its implications for the biosimilars business 

• Where and what are the market opportunities based on acceptance and therapeutic fit? 

• How do biosimilars fulfil the need for increasing access to medicines? 

Alan Sheppard, Principal, Global Generics, Thought Leadership, IMS Health, UK 

eXTernAl collABorATions & THe coMMerciAl VAlue oF BiosiMilArs 

0940 Shared Value Strategies – Partnerships to Strengthen Biosimilars Development 

• A look into global approaches to partnerships 

• An overview of the broad capabilities required for success in developing and commercializing biosimilars 

• How companies are utilizing partnerships to achieve these capabilities 

• Case Study Focus: Merck’s global alliance with Hanwha on etanercept 

• Collaboration Studies: clinical and manufacturing collaborations with Parexel and MedImmune 

Julie Seawall, Executive Director, Business Development, Merck BioVentures, USA 

1010 Outlasting the Competition – how Commercial Rights Deals are Evolving With The Times 

• Evaluating competition to in-license across different markets 

• How to ensure that the long-term view and goals are the same for all parties involved 

• Have the dynamics of a commercial licensing agreement changed? 

• How flexible do licensing agreements have to be now in the face of ownership rights, risk-sharing management etc? 

• Is it still possible to keep jewels through non-exclusive agreements? 

• As ROIs get harder to come by, how are in & out-licensing agreements working out? 

Moderator: 

Yariv Hefez, Director, Global Business Development & Alliance Management, Merck Serono, Switzerland 

panelists: 

Tadashi Matsumoto, President, ReqMed, Japan 

dr Karen Wen, President, Mycenax, Taiwan 

1050 Morning Refreshments 

1120 Breaking into Protectionist Markets 

• Protectionism abroad and locally – what it means for biosimilar companies 

• Identifying the local hurdles to new entrants 

• How does this fit with the global move towards healthcare cost reductions worldwide and how it translates to increased 

advocacy of biosimilars? 

Michael Corbo, Vice President & Chief Development Officer, Bio-enhancement Development Unit, pfizer, USA 


ConferenCe Day one • TuesDay 24 april, 2012 

ConferenCe Day TWo • WeDnesDay 25 april, 2012 

+65 6508 2401 

+86 21 2326 3680 

Attend the 

Post Conference 

Briefing for more 

detailed analysis 

and discussion 

1250 Networking Lunch 

reguLatory 

keynote 

viSionary PaneL 

diScuSSion 

LegaL 

debate 




1400 Will China Take Centrestage in the Biosimilars Play? 

• Moving up from copy biologics to commercially viable biosimilars - why and how would this happen? 

PaneL 

diScuSSion 

• Valuing and defending the lion’s share of biologic drugs, what are the pros and cons for Chinese companies to enter overseas 

markets in view of the prestigious price policy? 

• How are the relatively small Chinese biotech companies reaching out globally to the big pharmas for greater strategic 

collaborations? 

• How can local Chinese companies leverage available funds and good manufacturing practices to achieve global biosimilars 

standards to gain entry to established markets? 

Moderator: 

dr Joe Zhou, CEO, Genor Biopharma, China 

panelists: 

Song Jun, Business Development Manager, Strategy & Business Development, pfizer, China 


dr Yingfei Wei, CEO, Elixirin Corporation, USA 

Shirley Zhao, General Manager, Genzyme, China 

dr Xiaodong Yang, CEO, Apexigen, USA 

KeePinG uP WiTH GloBAl reGulATory eVoluTion 

1440 China’s Biosimilars Regulatory Environment 

• An overview of China’s 5 year plans and what it means to the biosimilar/biologics industry 

• The opportunities and challenges of the current China Biotech market and how lessons from other developed markets can 

be applicable here 


1510 Anticipating and Overcoming Regulatory hurdles of Biosimilar Development in US 

• Will President Obama’s proposed healthcare savings bill on shortening exclusivity and banning “pay for delay” deals be 

enacted soon and what would it mean for the biosimilars guidelines? 

• Deciding between ANDA, 505(b)(2) or PHSA – which route should Asian companies choose in order to enter US markets? 

• Will FDA publish a biosimilar guideline in favour of biosimilar companies? 

dr duu-Gong Wu, Executive Director, pharmaNet/i3, USA 

1540 Afternoon Refreshments 

1610 global Development for Biosimilars: The new Regulatory Paradigm? 

• An overview of the global regulatory environment for biosimilars 

• Key changes to expect in EMA’s revised biosimilar guidelines 

• What will be the impact on biosimilar developments? 

Suzette Kox, Senior Director Scientific Affairs, European Generic Medicines Association (EGA), Belgium 

1640 key Considerations in Developing a Practical Path From a Biosimilar Plan To Execution 

• What are the key issues needed to be addressed? 

• How to develop an integrated view of the biosimilar space? 

• What does it take to bring a biosimilar to the finish line? 

• Designing a viable path and executing based on interpretation of regulations 


1710 has the Industry Learnt from Commoditized generics or Does it Foretell the Bloodbath Ahead for 

Biosimilars? 

• Is there really a market for biosimilars post 2020 and before the next round of patent expires? 

• Balancing risks with returns from biosimilar vs biobetter – which holds greater commercial potential in the long term? 

• How will the industry prevent unsustainable price competition for biosimilars and biobetters? 

Moderator: 


panelists: 

dr Kyu don Kim, Vice President, Strategic Business development, Samsung, South Korea 


dr duu-Gong Wu, Executive Director, pharmaNet/i3, USA 

Tim Oldham, President, Asia Pacific, Hospira, Australia 

1750 Chairperson’s Remarks and End of Conference Day One 

Followed by Networking Reception 

1150 Strategies to Counter Aggressive Price Cuts in Biosimilars in Emerging Markets 

• Responding to innovators’ counterstrategies 

• Ensuring that there’s a balance between profitability and market penetration 

• How can biosimilar companies engage competitive pricing to compete with the originator? 

dr Subir Basak, Chief Executive Officer, Celestial Biologicals Limited, Chief Commercial Officer, 

Intas Biopharmaceuticals Ltd, India 

1220 Intellectual Property Opportunities and Challenges for Biosimilar Commercialization in Asia 

• Are patents irrelevant to the commercialization of 1st generation biosimilars in Asia? 

• Are process patents possible and valuable? 

• How do companies approach acquiring/building patent portfolios and assessing freedom-to-operate issues in Asia? 

• Will patents and other intellectual property drive deals in Asia? 

• Will patent enforcement play a significant role in driving company/product value in Asia? 

• How does intellectual property impact global commercialization strategies? 

Moderator: 

dr Janet McNicholas, Partner, K&L Gates LLp, USA 

panelists: 

Ye Hua, Senior Corporate Counsel, pfizer, China 

dr Yang Xu, Chief Patent Counsel, Simcere pharmaceutical Group, China 

dr Mandar Kodgule, Associate Vice President & Head, Global Intellectual Property & Strategic Planning, Wockhardt, India 

Anne dollard, Deputy General Counsel, Takeda San francisco, USA 

1300 Networking Lunch 

Part of 

MAd ABouT MABs – deVeloPinG BiosiMilArs & BioBeTTers 

1400 Biosimilars mAbs as the next “holy grail”? Winning the global Race for Markets 

• An overview of mAbs development globally 

• How big are the stakes for global biosimilar mAbs? 

• Is it really the “holy grail” or is it due to an arid R&D pipeline that companies are turning to mAbs for profits? 

• How will innovators defend against launches in emerging and established markets? 

dr Sunit Maity, Associate Divisional Head, Biopharmaceuticals, Avesthagen, India 

1430 Strategies for global Clinical Development of Biosimilars 

• Case Study: Celltrion’s global development of mAb biosimilars 

caSe 

Study 

+65 6508 2407 

+86 21 2326 3699 

• How to achieve the structural and functional comparability? 

• Key challenges during the trial and how they were overcome 

• Is it possible for a globally accepted biosimilar mAbs? 

dr Stanley Hong, Senior Vice President, Research & Development, Celltrion, South Korea 

register@ibcasia.com.sg www.biosimilarsasia.com


1500 Achieving Quality Biosimilars 

• How similar to the originator is acceptable? 

• What are the major concerns? 

• Detailed comparability and key markers to attain 

• Utilizing other indications to ensure the best quality of biosimilars is manufactured 


1530 Afternoon Refreshments 

WinninG Buy-in FroM PrescriBers & sTAKeHolders 

1600 Changing Market Perceptions: What Biosimilar Companies can do to Increase Acceptance 

• The current perception of biosimilars – does high acceptance equal high confidence? 

• Overcoming fears raised by innovators’ counter-detailing strategies through strategic investments in pre-launch marketing 

• Understanding and actively engaging public policy makers and payers to resolve the acceptance gap 

dr Shahzad Khan, Director, Marketing & Sales, Getz pharma, Pakistan 

1630 gaining greater Traction in the US – a Pharmacy Benefit Management (PBM) View on Biosimilars 

• Does being cheaper mean more attraction towards biosimilars? 

• What are the financial incentives and requirements for PBMs to start actively prescribing biosimilars 

• Under what conditions will PBMs offer a large co-pay to the patients 

Thomas Moriarty, President, Global Pharma Strategies, Medco, USA 

0800 签到及早茶 

0830 药物创制和开发周大会主席致开幕词 

Li Chen, President & CEO, Hua Medicine, China 


大会主题演讲 

全球药物研发与区域合作发展现状 

0840 武田制药的研发合作模式创新 - 贴近医患需求,积极推进靶向药物开发 

Dr Mary Haak-Frendscho, President & Chief Scientific Officer, Takeda San Francisco, USA 

全体小组讨论全球主题全球主题主题演讲 

演讲 

演讲 

0910 通过合作扩展创新网络 

Joe McCracken, Global Head of Business Development and Licensing, Roche, USA 

0940 有效应对研发生产力挑战:整合外部研究 

Dr Helmut Haning, Senior Vice President & Head Global Innovation Outsourcing, Bayer Healthcare Pharmaceuticals, 

Germany 

1010 中国是否做好准备,领导全球药品创新与发展? 

主持嘉宾: 

Carl Firth, Chief Executive Officer, Aslan Pharmaceuticals, Singapore 

讨论嘉宾: 

Frank Shen, Vice President Global Data Management and Statistics, Global Pharmaceutical R&D, Abbott, USA 

Ling Chen, Vice President of R&D China Operations, GlaxoSmithKline, China 

Ming Wang, Executive Director & Head of Diabetes Research, Amgen, USA 


1100 上午茶歇 

药物创制和开发周联合会议时段结束 

1130 2012 年亚洲生物仿制药会议主席致开幕词 

Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals, USA 

生物仿制药的未来:市场准入与机遇 

1140 生物仿制药的商业可行性 


1210 突破常规思维 — 进军监管法规不健全或无成熟监管体系的新兴医药市场 

主持嘉宾: 

Dr Tong Zhang, Director, Pan Regional Lead, Emerging Market Business Development, Merck, USA 

讨论嘉宾: 


Imtiaz Razzaq, Head of Business Development, Getz Pharma, Pakistan 

Dr Peter Qian, CEO, Reviva Biopharmaceutics, General Secretary, CBA, USA 

小组讨论 

0900 大会主席致开幕词 


生物仿制药的外部协作与商业价值 

0910 生物仿制药是否已踏上终结之路? 


0940 价值共享策略 — 展开合作,加强生物仿制药的开发 

Julie Seawall, Executive Director, Business Development, Merck BioVentures, USA 

小组讨论小组讨论投资者专题 

1010 在竞争中脱颖而出 — 商业权利交易如何与时俱进 

主持嘉宾 : 

Yariv Hefez, Director, Global Business Development & Alliance Management, Merck Serono, Switzerland 

讨论嘉宾: 

Tadashi Matsumoto, President, ReqMed, Japan 

Dr Karen Wen, Vice President, Mycenax, Taiwan 

1050 上午茶歇 

1120 敲开贸易保护大门 

Michael Corbo, Vice President & Chief Development Officer, Bio-enhancement Development Unit, Pfizer, USA 

1150 应对新兴市场生物仿制药大幅削价的策略 

Dr Subir Basak, Chief Executive Officer, Celestial Biologicals Limited, Chief Commercial Officer, 

Intas Biopharmaceuticals Ltd, India 

1220 生物仿制药相关知识产权在亚洲的面临的商业化机遇和挑战 

主持嘉宾: 

Dr Janet McNicholas, Partner, K&L Gates LLP, USA 

讨论嘉宾: 

Ye Hua, Senior Corporate Counsel, Pfizer, China 

Dr Yang Xu, Chief Patent Counsel, Simcere Pharmaceutical Group, China 

Dr Mandar Kodgule, Associate Vice President & Head, Global Intellectual Property & Strategic Planning, Wockhardt, India 

Anne Dollard, Deputy General Counsel, Takeda San Francisco, USA 

ConferenCe Day TWo • WeDnesDay 25 april, 2012 

+65 6508 2401 

+86 21 2326 3680 

cLoSing PaneL 

diScuSSion 

+65 6508 2407 

+86 21 2326 3699 




1700 ThE Biosimilar Question: Will We be able to Witness the Inception of a global Biosimilar? 

• What will it take for global biosimilars to exist? 

• The showdown between the rise of Asian mega-companies with deep pockets and long-term views vs Big Pharma 

• Will biosimilars be commercially successful in the marketplace or be beaten into 2nd place by the innovators ‘Established 

Products’ at unbeatable prices in emerging markets? 

Moderator: 


panelists: 


dr Arthur Alston, Regulatory Affairs, Special Projects, Roche, Switzerland 

dr Junichi Koga, Vice President Biopharmaceuticals, daiichi-Sankyo, Japan 

dr Mary Haak-frendscho, President & Chief Scientific Officer, Takeda San francisco, USA 

1740 Chairperson’s Closing Remarks and End of Conference 

会议第一天 • 2012年4月24日, 星期二 

1250 联谊午宴 

会议第二天 • 2012年4月25日, 星期三 

1400 中国企业应如何把握生物仿制药浪潮,扬帆前行? 

主持嘉宾: 

Dr Joe Zhou, CEO, Genor Biopharma, China 

讨论嘉宾: 

Song Jun, Business Development Manager, Strategy & Business Development, Pfizer, China 


Dr Yingfei Wei, CEO, Elixirin Corporation, USA 


Dr Xiaodong Yang, CEO, Apexigen, USA 

小组讨论 

1440 中国的生物仿制药监管环境 


监管专题 

小组前瞻讨论 

小组讨论 

紧跟全球监管变革的步伐 

1510 分析预测美国的生物仿制药开发监管障碍并探寻可行解决之道 

Dr Duu-Gong Wu, Executive Director, PharmaNet/i3, USA 

1540 下午茶歇 

1610 生物仿制药全球发展环境:监管新思维? 

Suzette Kox, Senior Director Scientific Affairs, European Generic Medicines Association (EGA), Belgium 

1640 制定可行方案,将生物仿制药计划付诸实践时应注意的重要事项 

Dr Ming Wang, Executive Director & Head of Diabetes Research, Amgen, USA 

1710 如何从化学仿制药的发展中吸取经验教训?生物仿制药行业如何才能避免重蹈覆辙,脱离成本血 

战的残酷命运? 

主持嘉宾: 


讨论嘉宾: 

Dr Kyu Don Kim, Vice President, Strategic Business Development, Samsung, South Korea 

Dr Ming Wang, Executive Director & Head of Diabetes Research, Amgen, USA 

Dr Duu-Gong Wu, Executive Director, PharmaNet/i3, USA 

Tim Oldham, President, Asia Pacific, Hospira, Australia 

1750 大会主席致词,第一天议程结束,随后举行联谊酒会 

1300 联谊午宴 

开发生物仿制药和生物改良药 

1400 单克隆抗体生物仿制药是否会成为市场的下一个“圣杯”? 领跑全球市场份额之争 

Dr Sunit Maity, Associate Divisional Head, Biopharmaceuticals, Avesthagen, India 

1430 生物仿制药全球临床开发策略 

Dr Stanley Hong, Senior Vice President, Research & Development, Celltrion, South Korea 

1500 研发高效生物仿制药 


1530 下午茶歇 

赢得处方医师和利益相关者的支持 

1600 改变市场观念:生物仿制药企业可以采取哪些措施提高市场认同度 

Dr Shahzad Khan, Director, Marketing & Sales, Getz Pharma, Pakistan 

1630 如何在美国占有更多市场份额?——生物仿制药医药福利管理 (PBM) 分析 

Thomas Moriarty, President, Global Pharma Strategies, Medco, USA 

1700 有关生物仿制药的终极疑问 : 我们有生之年是否能有幸目睹生物仿制药进入全球大发展的新 

时代? 

主持嘉宾: 


讨论嘉宾: 


Dr Arthur Alston, Regulatory Affairs, Special Projects, Roche, Switzerland 

Dr Junichi Koga, Vice President Biopharmaceuticals, Daiichi-Sankyo, Japan 

Dr Mary Haak-Frendscho, President & Chief Scientific Officer, Takeda San Francisco, USA 

1740 大会主席致词, 会议结束 

register@ibcasia.com.sg www.biosimilarsasia.com 

Part of


DISCUSSIOn DEn 

Industry experts will facilitate discussions on top challenges to foster the sharing of experience and best practices. This is a rare opportunity to engage in a candid, interactive setting 

focused on ongoing and emerging mutual challenges. Groups are limited and advance signup onsite is encouraged to ensure your seat. These discussions will run simultaneously with the 

main conferences and is open to all attendees. 

Pre-conference day Workshop: 

23 April 2012, Monday 

This full-day workshop will run from 09:00 – 17:00, 

with mid-morning and afternoon refreshment breaks 

and lunch. Registration begins from 08:30 

会前研讨会:2012年4月23日, 

星期一 (上午9:00 — 下午5:00) 

A: U.S. Market 

Entry: A Regulatory, 

Legal, and Medical 

Communication 

Perspective 

进入美国市场:从监管、 

法律和医学交流角度进行 

分析 

Post-conference day Briefing: 

26 April 2012, Thursday 

This full-day workshop will run from 09:00 – 17:00, 

with mid-morning and afternoon refreshment breaks 

and lunch. Registration begins from 08:30 

会后通报会:2012年4月26日, 

星期四 (上午9:00 — 下午5:00) 

B: Turning Strategies 

into Tactical Plans to 

Optimize Market Entry – 

Balancing Commercial, 

Regulatory and 

Investments to Deliver 

Successful Business 

Models 

运筹最佳上市时机 — 生物 

仿制药推向市场的思考与 

机遇 

TuesDay 24 april, 2012 WeDnesDay 25 april, 2012 

1130 Partnering in Biosimilars mAbs 

Robert Chen, Director, Global Strategy & Partnering, Genor Biopharma, China 

1230 Aligning R&D and Drug Safety 

协调研发与药品安全 

James Yan, Executive Director, Hutchison Medipharma, China 

1415 Understanding the Virtual Drug Development Model 

Stephen porter, CEO, VddI pharmaceuticals, USA 

1500 Successful Licensing Strategies for the Chinese Biotech 

中国生物技术的成功许可策略 

Allan Riting Liu, Vice President/Senior Advisor, Wanbang Biopharmaceutical Group, 

Vice President, fosun pharmaceutical, China 

1610 R&D Project Management & Strategy 

研发项目管理与策略 

Kumar penmetsa, Senior Director, Project Management and Strategic Operations, 

Bristol Myers Squibb, China 

Objectives: 

To understand the opportunities and challenges for entering the U.S. Market from 

a Regulatory, Business Development, Law, and Communications perspective. It is 

important to take these issues into consideration together to create a successful 

market entry strategy. 

Who Should Attend: 

Anyone interested in entering the U.S. market to understand the challenges involved 

and how to position themselves to succeed in entering the U.S. market. 

Outline: 

• Introduction: Case Study of Entering U.S. Market 

• Regulatory Considerations for R&D: Strategies to Save Time and Money Towards 

Future FDA Approval 

• Protecting your IP in the U.S.: When to File for IP with Changing U.S. Law 

• Filing for Regulatory Approval: Approaches for Handling New FDA 

• Communications Strategies: Medical Communications to Support Commercial 

Success 

• Developing Partnerships: Mergers and Acquisitions, Joint Ventures, Capital 

Raises 

• Clinical Trials: Strategies for Successful Trials 

• Launching your Product: Case Study, Getting your Product into the Hands of 

Clinicians 

Workshop Agenda: 

• An overview of the challenges and opportunities in the biosimilars market 

~ Tactics employed by originator companies to counter biosimilars 

~ Selecting country of origin in certain market tenders to facilitate registration 

~ Impact of second generation molecules being launched prior to availability of 

first generation biosimilars 

~ Requirement and access to an EU CPP for qualification in tendering 

• Biosimilars in the Asian pharmerging markets, positioning and opportunities 

~ China ~ Philippines ~ Bangladesh 

~ India ~ Malaysia ~ Taiwan 

~ Vietnam ~ Singapore ~ Hong Kong 

~ Thailand ~ South Korea 

~ Indonesia ~ Pakistan 

• What are the various market entry strategies for Biosimilars in the above 

markets? 

• Tailoring targeted launch strategies 

• Strategic pricing strategies used by originators to retain volume sales and reduce 

attraction of biosimilars 

~ Implications of such actions in MENA, LATAM and APAC emerging markets 

• What intellectual property challenges lie ahead? 

~ Potential for an Invalidation Strategy for 8,063,182 Roche patent on etanercept 

expiring 11/22/28 

~ Cabilly II and III: An insurmountable hurdle or a reason for negotiation? 

• What is the recommended legal due-diligence needed before entry into 

pharmerging countries? 

• The importance of an essential drug’s list and inclusion 

• The acceptance by regulators of a global development programme for biosimilars 

to speed access to markets and harmonise requirements 

0915 Biocomparability in Biosimilars: Conducting BA/BE studies 

Chichang Lee, Vice President of Preclinical & Cell line Development, ZheJiang Teruisi, 

China 

1135 Dealing with Legal and IP Issues in Entering the US Market 

打入美国市场需要应对的法律和知识产权问题 

Gary Arlen Smith, Founder, Enterprise Law, USA 

Part of 




1320 Innovative Drug Development in China 

中国创新药物开发 

Jingzong qi, Vice President & Director of Clinical Research Center, fusoGen 

pharmaceuticals, China 

1400 Leading a China Team Towards Drug Development: Medical Director’s 

Perspective 

Jean denis Shu, Medical Director, Sanofi pasteur, China 

Led By: 

Seth J. Goldenberg, President, Asia Pacific Bio Intelligence, former u.S. 

fdA, pharmacology 

Seth is a former Regulatory Chemist with the FDA and current President of 

APBI. He holds a PhD in Pharmacology from the University of Washington 

and a M.S. from the School of Biomedical Engineering at Drexel University. He has 

a strong record in drug development, FDA, business development, product licensing, 

grant writing, scientific patents, medical communications, and collaborations with 

academia and industry. Dr Goldenberg understands not only what it takes to carry out 

scientific study, but also the importance of communicating it with the global scientific 

community to foster partnerships and collaboration. 

Michael platt, President, MedVal Communications, USA 

Michael comes to MedVal from Fission Communications, a New York-based 

medical education and communications company he co-founded in 2001. 

He has over 16 years of industry experience and a broad knowledge of the 

pharmaceutical, biotechnological, and healthcare marketing fields, as well as additional 

expertise in cardiology, allergy and asthma, infectious disease, gastroenterology, 

urology, rheumatology, oncology, and HIV. 

Gary Arlen Smith, Founder, Enterprise Law, USA 

Gary is founder and principal of Enterprise Law Associates, LLC, a boutique law 

firm serving life science and technology companies in all stages of their life cycles 

from pre-startup through exit. Prior to founding ELA, Gary was Vice President 

and General Counsel of Tengion, Inc., served as Vice President and General Counsel of 

Enzon Pharmaceuticals, Inc., was engaged in private law practice for 15 years and was a 

partner in the law firms Morgan, Lewis & Bockius and Ballard Spahr and Saul Ewing. 

Led By: 

Alan Sheppard, Global Head of Generics, Thought Leadership, IMS Health 

Alan has over 35 years’ experience within the pharmaceutical industry covering 

the full spectrum of innovative medicines, generics, biologicals, vaccines and 

OTC medicines. His previous career positions include Executive VP, Europe 

Generics, Dr Reddy’s Laboratories and VP, Global Corporate Strategy, Pliva. Alan was a 

long serving member of the Prescription Medicines Code of Practice Authority Appeals 

Board, Fellow of the Institute of Management, Member of Chartered Marketing and 

Fellow of the International Doctors’ Association. 

Richard diCicco, Chairman, Harvest Moon pharmaceuticals uSA, Inc 

Co-founded in 2007, with a proven pipeline of products developed since 1984, 

HMP develops and licenses-out to the trade, worldwide, complex generic drug 

products, copy bio products and biosimilars. Rich is a member of the Editorial 

Board of the Journal of Generic Medicines, a member of the Licensing Executives 

Society and is widely published in generics and biosimilars. 

Janet M McNicholas, Partner, K&L Gates LLp 

Janet has headed the biotechnology patent practice at McAndrew, Held and 

Malloy, the Life Sciences Patent Group of Cooley Godward in Palo Alto and 

served as patent counsel for XOMA, a biotechnology company known as a 

leader in the development of therapeutic antibodies. Prior to practicing law, Janet 

conducted research in immunology, molecular biology, biochemistry and genetics 

at Stanford University and at the California Institute of Technology through a postdoctoral 

fellowship. 

Featuring Latest Updated Intelligence from:

If undelivered, please return to: 

1 grange road, 

#08-02, Orchard Building, Singapore 239693 

tel: +65 6508 2400 Fax: +65 6508 2408 

ReseRve youR place today! 今天预定席位! 

SAVE WITh ThE EARLy BIRD 

& SPECIAL RATES! 

享受预定优惠价和特别优惠价 

3 Rd annual BiosimilaRs asia 2012 2012年亚洲生物仿制药会议 

This label contains your priority booking code. To expedite registration, please do not remove label. If you have already received a copy of this brochure, 

we apologise. For reasons of confidentiality, your full particulars were not available to IBC Asia (S) Pte Ltd for dedupulication prior to mail drop. 

q yes! i/We will attend 3rd annual Biosimilars asia 2012, 23– 26 april 2012, Grand Hyatt shanghai, china 

q I would like to purchase the conference presentations at USD$688 per log in. 

fees peR deleGate eaRly BiRd 

Register and pay before 

10 Feb 2012 

p46189 

enJoY sUBstantial saVings With 

oUR MUltiPle BooKing DisCoUnt! 

Register 3 delegates from the same company and the 

4th delegate attends FREE! 

5 easy Ways to ReGisteR 5种便捷的报名方式 

MAIl the attached registration form with your cheque to 

将随附的登记表及支票邮寄至 

iBc asia (s) pte ltd c/o informa Regional Business services 

1 Grange Road, #08-02, orchard Building, singapore 239693 

Customer Service Hotline 客户服务热线 

+65 6508 2401 (sinGapoRe) 

+86 21 2326 3680 (cHina) 

Email 电子邮件 

register@ibcasia.com.sg 

• 6% Business Tax is applicable to all companies paying in CNY. 

• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee stated is the discounted price PER DELEGATE. Only one 

discount applies – either the early bird rate OR special rate or group rate. 

• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel. 

delegate 1 details 

Name: Dr/Mr/Ms 

Job Title: 

Department 

Tel: Mobile No.: 

Email: 



Job Title: 

Department 


Email: 

Who is Head of your Department? 

Who is Head of Training? 



company information 

Company Name: Main Business/Activity: 

Address: Postal Code: 

Payment Method (please tick): I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd 

I am paying by bank transfer (copy attached) 

Payment by credit card. (AMEX, VISA or MasterCard accepted) 

credit card Payments 

The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at www.biosimilarsasia.com and click “Register On-line”. 

If you would prefer to pay over the phone please complete the contact name and details and our Customer Services Team will call within 24 hours to take payment. As we treat 

your credit card information in the strictest confidence, please do not send payment details by email. 

Job Title: 

Department 

Credit card contact: Department: 

Direct phone number: Email: 


Email: 



Job Title: 

Department 


Email: 

special Rate 


16 Mar 2012 

noRmal Rate 

Register and pay after 

16 Mar 2012 

GRoup Rate 

GRoup Rate 

(3 oR moRe) 

q 4 Day Pass: Conference + Workshops A + B USD 2,695 USD 2,895 USD 2,995 USD 2,495 

q 3 Day Pass: Conference + q Workshop A or q Workshop B USD 2,295 USD 2,495 USD 2,595 USD 2,095 

q 2 Day Pass: Conference only USD 1,695 USD 1,895 USD 1,995 USD 1,495 

to attend 1 additional co-located event, additional fee: usd 250 (cny 1,600) peR additional event which includes access to event documentation. 

the multi access pass is not transferable and allows access to 2 or more named events 

domestic cHina companies only 

fees peR deleGate 

eaRly BiRd 


10 Feb 2012 

special Rate 


16 Mar 2012 

noRmal Rate 

Register and pay after 

16 Mar 2012 

GRoup Rate 

GRoup Rate 

(3 oR moRe) 

q 4 Day Pass: Conference + Workshops A + B USD 1,795 USD 1,995 USD 2,095 USD 1,895 

q 3 Day Pass: Conference + q Workshop A or q Workshop B USD 1,595 USD 1,795 USD 1,895 USD 1,695 

q 2 Day Pass: Conference only USD 1,195 USD 1,295 USD 1,395 USD 1,295 

Please photocopy for additional delegates 

REGISTER NOW! FAX BACK TO +65 6508 2407 立即报名! 传真到 +65 6508 2407 

Fax 传真 

+65 6508 2407 (singapore) 

+86 21 2326 3699 (china) 

Web 网络 

www.biosimilarsasia.com 

Hotel infoRmation 

Grand Hyatt shanghai, china 

Jin Mao Tower, 88 Century Boulevard, 

Pudong, Shanghai 200121 

Tel: 86 21 5047 1234 Ext. 8550 

Fax: +86 21 5049 8381 

Contact Person: Juno Zhu 

Email: Juno.Zhu@hyatt.com 

payment teRms 

Payment must be received 10 business days prior 

to the event. To take advantage of discounts with an 

expiry date, registration and payment must be received 

by the cut-off date. 

• payment by bankers draft or cheque in us$ 

should be made in favour of IBC Asia (S) Pte ltd 

and mailed to: IBC Asia (S) Pte ltd 

c/o Informa Regional Business Services 

111 Somerset Road, TripleOne Somerset #10-06 

Singapore 238164 

Attn: The Accounts Receivable Team 

• Payment by bank transfer in US$ made payable 

to: IBC Asia (S) Pte ltd 

A/C No.:147-059513-001 (S$) 

A/C No.:260-457866-178 (US$) 

The Hongkong and Shanghai Banking Corporation 

limited 

21 Collyer Quay, HSBC Building Singapore 049320 

Bank Swift Code: HSBCSGSG 

Bank Code: 7232 

• Payment by CNY 

Account Name: 艾毕思会务服务(上海)有限公司 

Account No. 720-031103-001 

Beneficiary Bank: 汇丰银行(中国)有限公司上海分行 

Bank Address: No.1000 lujiazui Ring Road, 

Pudong, Shanghai 200120 P.R.China 

• Payment by credit card in US$ 

(AMEX, VISA or MasterCard) 

The best way to pay by credit card is through our 

secure portal built into the website. To pay by phone 

please indicate the contact name and details below 

and our Customer Services Team will call within 24 

hours to take payment. Please do not send credit 

card information by email. 

cancellations / suBstitution 

Should you be unable to attend, a substitute delegate 

is welcome at no extra charge. Cancellations must be 

received in writing at least 10 business days before 

the start of the event, to receive a refund less 10% 

processing fee per registration. The company regrets 

that no refund will be made available for cancellation 

notifications received less than 10 business days 

before the event. 

impoRtant note 

Please quote the name of the delegate, event title and 

invoice number on the advice when remitting payment. 

Bank charges are to be deducted from participating 

organisations own accounts. Please fax your payment 

details (copy of remittance advice, cheque or draft to 

+65 6508 2407. Attendance will only be permitted upon 

receipt of full payment. Participants wishing to register 

at the door are responsible to ensure all details are 

as published. IBC Asia will not be responsible for any 

event re-scheduled or cancelled. 

data pRotection 

The personal information entered during your 

registration/order, or provided by you, will be held on 

a database and may be shared with companies in the 

Informa Group in the UK and internationally. Sometimes 

your details may be obtained from or shared with 

external companies for marketing purposes. If you 

do not wish your details to be used for this purpose, 

please contact the Winnie Seah (Database) on 

winnie.seah@ibcasia.com.sg Ph: +65 6508 2468 or 

Fax: +65 6508 2408. 

REG NO. 200108203N

REGISTER TOday! - Bentham Science

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?